scholarly journals The Role of the Stem Cells Therapy in the Peripheral Artery Disease

2019 ◽  
Vol 20 (9) ◽  
pp. 2233 ◽  
Author(s):  
Federico Biscetti ◽  
Nicola Bonadia ◽  
Elisabetta Nardella ◽  
Andrea Leonardo Cecchini ◽  
Raffaele Landolfi ◽  
...  
Keyword(s):  
Stem Cells ◽  
Vascular Complications ◽  
Arterial Disease ◽  
Definitive Treatment ◽  
Stem Cells Therapy ◽  
Artery Disease ◽  
The Moment ◽  
Peripheral Arterial

Vascular complications of diabetes mellitus are an important issue for all clinicians involved in the management of this complex pathology. Although many therapeutic advances have been reached, peripheral arterial disease is still an unsolved problem that each year compromises the quality of life and life span of affected patients. Oftentimes, patients, after ineffective attempts of revascularization, undergo greater amputations. At the moment, there is no effective and definitive treatment available. In this scenario, the therapeutic use of stem cells could be an interesting option. The aim of the present review is to gather all the best available evidence in this regard and to define a new role of the stem cells therapy in this field, from biomarker to possible therapeutic target.

scholarly journals Marine and plant-based n-3 PUFA and atherosclerotic cardiovascular disease

2019 ◽  
Vol 79 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Christian S. Bork ◽  
Stine K. Venø ◽  
Anne N. Lasota ◽  
Søren Lundbye-Christensen ◽  
Erik B. Schmidt
Keyword(s):  
Ischaemic Stroke ◽  
Arterial Disease ◽  
Atherosclerotic Cardiovascular Disease ◽  
Peripheral Artery ◽  
Ascvd Risk ◽  
Artery Disease ◽  
Atherosclerotic Process ◽  
Peripheral Arterial

n-3 PUFA may exert favourable effects on several processes that may inhibit the atherosclerotic process. However, the role of n-3 PUFA in lowering the risk of atherosclerotic CVD (ASCVD) has been fiercely debated. In the present paper, we summarise the main findings from previous follow-up studies of intake and studies using adipose tissue as an objective biomarker to investigate exposure to n-3 PUFA in relation to ASCVD risk and discuss some perspectives for further research. The majority of previous studies investigating intake of marine- and plant-based n-3 PUFA have focused on CHD while other ASCVD such as ischaemic stroke and peripheral artery disease have been less studied. However, recent data from Danish Diet, Cancer and Health cohort suggest that marine n-3 PUFA may be inversely associated with risk of myocardial infarction, ischaemic stroke and peripheral arterial disease caused by atherosclerosis. The effect of the plant-derived n-3 PUFA α-linolenic acid on ASCVD is less clear and several gaps in the literature remain to be explored.

scholarly journals Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease

2021 ◽  
Vol 4 ◽  
Author(s):  
Ceazón T Edwards ◽  
Peter A Schneider ◽  
Cindy Huynh
Keyword(s):  
Dose Response ◽  
Meta Analysis ◽  
Arterial Disease ◽  
Long Term Results ◽  
Real Patient ◽  
All Cause Mortality ◽  
Artery Disease ◽  
Peripheral Arterial

The role of paclitaxel in the treatment of femoropopliteal peripheral arterial disease is currently ambiguous. A summary-level meta-analysis of randomised trials published in 2018 demonstrated that paclitaxel-coated devices were associated with an increased all-cause mortality in those who underwent treatment at 2 years and 5 years. Further evaluation has been undertaken to establish whether there is a specific dose response, mechanism or reproducible signal. At this time, there has been no confirmation of dose response, as was initially asserted by the summary-level meta-analysis. No mechanism of harm has been identified. Although an association with increased mortality has been confirmed by patient-level meta-analysis, the strength of the signal has been inconsistent. The information suggests there is only an association between paclitaxel-coated devices and increased all-cause mortality, not causation. The authors encourage additional studies designed to follow long-term results after treatment with paclitaxel-coated devices, using real patient data, before a conclusion can be made.

scholarly journals The Toll of Vascular Insufficiency: Implications for the Management of Peripheral Arterial Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Jun Xu ◽  
Ulka Sachdev
Keyword(s):  
Arterial Disease ◽  
Toll Like Receptor ◽  
Tlr Signaling ◽  
Cardiovascular Research ◽  
Vascular Insufficiency ◽  
Cardiovascular Biology ◽  
Arterial Insufficiency ◽  
Artery Disease ◽  
Peripheral Arterial

Peripheral artery disease (PAD) can result in limb loss within six months of diagnosis in a subset of patients who cannot undergo endovascular or surgical revascularization yet continues to maintain a marginal position in cardiovascular research. While a body of literature continues to grow describing the role of danger signaling and innate immunity in cardiac biology, the role of these pathways in the ischemic myopathy associated with PAD has not been extensively studied. The following report will review the current literature on the role of Toll-like receptor (TLR) signaling in cardiovascular biology as well as in nonischemic myopathy. While attenuation of TLR signaling has not been shown to be clinically useful in the treatment of infectious inflammation, it may show promise in the management of severe arterial insufficiency.

scholarly journals Statins in Peripheral Arterial Disease

2018 ◽  
Vol 23 (46) ◽  
pp. 7099-7108 ◽  
Author(s):  
Scott T. Chiesa ◽  
Nikos Papageorgiou ◽  
Marietta Charakida
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
Lipid Lowering ◽  
Cardiovascular Morbidity And Mortality ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Pleiotropic Actions

Peripheral arterial disease (PAD) is a common atherosclertico condition affecting the lower extremities. PAD patients share similar cardiovascular risk factors to coronary artery disease patients and suffer from increased cardiovascular morbidity and mortality. Statins have been widely used in coronary artery disease patients but have been underused in patients with PAD. In the current review, we present data which support the beneficial role of statins in both reducing cardiovascular events and improving symptom-related outcomes in PAD patients. Alongside their lipid lowering effects, their pleiotropic actions are also discussed. Recent guidelines, which strongly recommend the administration of statins in PAD patients, are also presented.

scholarly journals Correlations of the Mechanisms Involved in Diabetes Mellitus, Peripheral Arterial Disease and Gangrene Leading to Amputations-a Retrospective Study Over the Non-traumatic Amputations Performed in the Emergency Clinical County Hospital of Arad Between 2014- 2018

2019 ◽  
Vol 70 (9) ◽  
pp. 3309-3314
Author(s):  
Roxana Furau ◽  
Amorin Remus Popa ◽  
Cristian Furau ◽  
Cringu Ionescu ◽  
Mihai Dimitriu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Arterial Disease ◽  
Control Measures ◽  
Premature Deaths ◽  
Disability Adjusted Life ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Disability Adjusted Life Year

Diabetes mellitus (DM) is, undoubtedly, an important risk factor of peripheral artery disease (PAD), leading to increased and severe complications, as well as for primary or associated dermatological lesions, all of which leading to radical therapeutic measures, as amputations are. DM and its complications have an important effect on life expectancy and quality of life, which can be quantified using disability-adjusted life year (DALY) as universal metric that allows researchers and policymakers to compare very different populations and health conditions across time. In the last five years these medical conditions have had a detrimental effect on the whole Arad County society, with a magnitude of premature deaths (YLL ) of 1,779 years and a value for Years Lost due to Disability (YLD) of 20,795, DALY reaching 22,574. These figures have to change completely the existent DM control measures for better protection of patients� health and improving their quality of life.

Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention

Vascular ◽  
2018 ◽  
Vol 27 (3) ◽  
pp. 299-311 ◽  
Author(s):  
Amer Harky ◽  
Perry Maskell ◽  
Mika Burgess
Keyword(s):  
Peripheral Artery Disease ◽  
Arterial Disease ◽  
Peripheral Artery ◽  
Randomized Controlled ◽  
Major Cardiovascular Events ◽  
Co Morbidity ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Meta Analyses

Objective Peripheral artery disease is a major clinical co-morbidity that can significantly affect quality of life, especially in the presence of diabetes mellitus and older age. The focus of this literature review is on medical management, through anti-platelet and anti-coagulation, of peripheral artery disease prior to undergoing surgical or endovascular management. Method Extensive electronic literature search performed in four major databases (PubMed, SCOPUD, Embase and Ovid) to identify the published randomized and non-randomized studies that compared and discussed the management of peripheral artery disease with different anti-thrombotic agents. Results A total of 17 studies were identified to meet the inclusion criteria of this review. Among them, 4 were systematic review and meta-analyses, 1 was observational study and 12 were randomized controlled trials. The reported outcomes in each study are summarized and reported separately within this review. Conclusion Peripheral artery disease is a complex and multifactorial clinical condition. The use of dual anti-platelets, such as aspirin and clopidogrel, are the key in preventing major cardiovascular events as well as stroke and death. Utilization of anti-coagulation such as direct oral anti-coagulants’ as additional parameters for the prevention of disease progression, is paramount. Eventually, the choice of either dual-antiplatelet therapy or combined anti-coagulation with anti-platelets should be carefully considered, particularly following the most recent published debatable studies.

Peripheral arterial disease in women

ESC CardioMed ◽  
2018 ◽  
pp. 2844-2845
Author(s):  
Mariana Garcia
Keyword(s):  
Quality Of Life ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cardiovascular Diseases ◽  
North America ◽  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
Artery Disease ◽  
Peripheral Arterial

Atherosclerotic disease involving the lower extremities, also known as peripheral arterial disease (PAD), has an estimated prevalence of 27 million adults in Europe and North America. PAD is now known to be associated with morbidity and mortality equal to coronary artery disease and stroke, and is associated with a significantly reduced quality of life. Awareness of PAD, both in women and men, is remarkably low compared to knowledge of other cardiovascular diseases.

scholarly journals Emerging Role of High Mobility Group Box-1 in Thrombosis-Related Diseases

2018 ◽  
Vol 47 (4) ◽  
pp. 1319-1337 ◽  
Author(s):  
Han Wu ◽  
Ran Li ◽  
Li-Gang Pei ◽  
Zhong-Hai Wei ◽  
Li-Na Kang ◽  
...  
Keyword(s):  
High Mobility ◽  
Arterial Disease ◽  
High Mobility Group ◽  
Toll Like Receptor 4 ◽  
Close Link ◽  
Molecular Pattern ◽  
Glycation End Products ◽  
Artery Disease ◽  
Peripheral Arterial

High mobility group box-1 (HMGB-1), a typical damage-associated molecular pattern protein released from various cells, was first identified in 1973. It is usually stored in the nuclei of cells. Several modifications of HMGB-1 promote its translocation to the cytosol, and it is actively or passively released from cells. When outside of the cells, HMGB-1is crucial in inflammation. It exerts its biological functions via interaction with its receptors, including receptor for advanced glycation end products (RAGE) and Toll-like receptor 4(TLR4). A large number of studies showed a close link between inflammation and thrombosis. This review demonstrated the increased expression of HMGB-1 in thrombosis-related diseases, including coronary artery disease, stroke, peripheral arterial disease, disseminated intravascular coagulation, and venous thrombosis. Besides, it summarized the current understanding of the emerging link between HMGB-1 and thrombosis from three aspects: platelet, NETs, and coagulation and fibrinolysis factors. Finally, it explored the possible therapeutic strategies targeting HMGB-1 for treating thrombosis-related diseases.

Sign in / Sign up

Export Citation Format

Share Document